Oral Squamous Cell CarcinomaOSCCNCT05150509
Association of Salivary Amino Acid Level With OSCC Identified By Liquid Chromatography Mass Spectroscopy
An observational study of Oral Squamous Cell Carcinoma, run by DR. MALA KHAN at 2 sites in Bangladesh.
Trial summary
Oral Squamous Cell Carcinoma (OSCC) is the most common oral malignancy worldwide. The prognosis of the OSCC patient is not significant despite the modern treatment facilities. Late presentation is one of the most crucial cause of this and for that reason, the importance of early diagnosis of OSCC should be the main… Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Oral Squamous Cell Carcinoma
- What is being tested?
- Oral Squamous Cell Carcinoma
- Type of treatment
- Pill or oral medicine
- How many people
- 110 participants
- Where
- 2 sitesBangladesh
- Study dates
- 15 Dec 2020to 30 Mar 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: Patients and their attendants attending in outdoor and indoor clinic of Oral and Maxillofacial Surgery Department, BSMMU according to inclusion and exclusion criteria. Total sample size will be 110 and 55 in each group. Cases are the oral squamous cell carcinoma patients confirmed by incisional biopsy and controls are the relatively same age group and healthy individuals.
Who may be able to join
- Age: 18-70 years.
- Both genders.
- Patient with histo-pathologically diagnosedoral squamous carcinoma
- Willing to participate in the study. Inclusion criteria for controls
- Healthy patients without any malignancy
- Patients relatively almost the same age group of cases
Who cannot join
- Patients with severe periodontitis and multiple carious teeth.
- Patients having other systemic diseases and cancer.
- Patients who cannot fulfill the inclusion criteria. Exclusion criteria for controls
- Having severe periodontal problemsor dental caries
- Suffering from any cancer
Trial locations and contacts
2 sites in 1 country.
Bangladesh2 sites, 2 recruiting
- Recruiting
Bangladesh Reference Institute for Chemical Measurements
Dhaka, Dhanmondi, 1205
Mala Khan, Dr., +88017-15032057, dg@bricm.gov.bd
Mamudul Hasan Razu, MS
- Recruiting
Bangabandhu Sheikh Mujib Medical University (BSMMU)
Dhaka, 1000
Dr. Mahmuda Akhter, Asst. Prof., +8801713063778, mahmudanaz@gmail.com
Prof. Md. Wares Uddin, BDS, +8801977382278, wares_bsmmu63@gmail.com
About this study
Official title: Association of Salivary Amino Acid With Oral Squamous Cell Carcinoma Identified by Liquid Chromatography Mass Spectroscopy
Oral Squamous Cell Carcinoma (OSCC) is the most common oral malignancy worldwide. The prognosis of the OSCC patient is not significant despite the modern treatment facilities. Late presentation is one of the most crucial cause of this and for that reason, the importance of early diagnosis of OSCC should be the main concern. Till now, incisional biopsy followed by histopathological examination is the gold standard for diagnosis of oral cancer. The aim of the present study is to find out the association of salivary amino acid levels with oral squamous cell carcinoma, whether the levels are increased or decreased in the patient suffering from OSCC. This might be helpful for early diagnosis of oral cancer and better prognosis.
Read the detailed description
- Introduction: Oral cancer is an abnormal growth of tissue, originates from the tissue in and around the mouth which is uncoordinated with that of the surrounding normal tissue. Among all oral cancers, oral squamous cell carcinoma (OSCC) is the most common (90%) malignant epithelial neoplasm of the oral cavity. It is an alarming public health problem in the world due to its prevalence, high incidence rate and mortality. According to the recent data of GLOBOCAN 2020, 377713 newly diagnosed lip and oral cavity squamous cell carcinoma patients diagnosed worldwide which is about 2% of all cancer reported. Oral squamous cell carcinoma (OSCC) is the 6th most common cancer worldwide. Recent global reports suggest that the largest portion of the reported cases are from Asia (65.8%), but in the South Asia region, oral cancer is the 3rd most common cancer. One of the critical factor of the high mortality rate of OSCC is that initially many of the lesion is asymptomatic. As a result, they come at the late stage of the disease to the physician and ultimately have a poor prognosis. Research showed that, when an OSCC is in stage I, the 5-year survival rate is 80% but it drops to 20-40% when the disease is in stage IV. For the diagnosis of OSCC, after the initial clinical examination, incisional biopsy followed by histopathological examination is still considered as a gold standard, but the method has many limitations. Invasive procedure needs special expertise for taking biopsy sample from the representative areas and need expert histopathologist for confirmation. Moreover, taking a tissue sample from behind the visible area such as the base of the tongue, posterior pillar and incase of restricted jaw opening is very difficult or sometimes impossible. Human saliva is the secretion from three major salivary gland parotid, submandibular, sublingual and numerous minor glands lie just beneath the mucosa of the oral cavity. It consists of water (99.5%), inorganic salts and enzymes (0.2%) and proteins (0.3%). It is helpful for the diagnosis of periodontitis, diabetes mellitus, HIV, dengue, mumps even breast cancer, pancreatic cancer, gastric cancer, lung cancer and oral cancer. Additionally, taking saliva samples has many advantages. Taking saliva is easier, and needs no invasive procedure or expertise. Besides, it has a sufficient amount of production and can be taken by the patient himself making the sample taking procedure cheaper. Salivary amino acids are the important metabolites for the diagnosis of a cancer patient. Amino acid is the raw product of protein synthesis. For this, when a cancer patient passes through a hypermetabolic and hypercatabolic state, there is a chance of protein imbalance. As the investigators know that amino acids are the byproducts of protein, it can give us a hint for the state of imbalance due to any cancer including oral squamous cell carcinoma. In addition, changes in amino acid concentration in the body fluid of cancer patient is significant according to several studies Mass spectrometry is a currently used platform for proteomics or metabolomics in biomedical research. Like other spectrometry method such as gas chromatography-mass spectrometry (GC-MS), capillary electrophoresis-mass spectrometry(CE-MS), two-dimensional electrophoresis mass spectrometry (2DE-MS), matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF) and surface enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI-TOF), Liquid chromatography-mass spectrometry (LC-MS) is widely used nowadays. It allows a quick and efficient separation and characterization of analytes in a given sample. Thus, it can help in rapid diagnosis of any disease by automated analysis of amino acid profiles with minimum effort and expenses. Many studies were conducted using LC-MS machine for saliva analysis for the diagnosis of several diseases and found significant results. To the best of my knowledge, very few studies were done to find out the salivary amino acid level from the patient having suspected oral lesion by LC-MS. Moreover, no study was performed for oral lesion diagnosis by analysis of amino acid profile using LC-MS in Bangladesh. The aim of this study is to find out the association of specific salivary amino acid levels with the patient of OSCC by Liquid Chromatography-Mass Spectrometry (LC-MS).
- Rationale: OSCC is the 6th most common cancer worldwide, but in Asia the largest portion was reported recently and in South-east Asia, it is the 3rd most common cancer. Poor socio-economic condition, lack of consciousness and widely use of tobacco, betel quid chewing and alcohol intake are the main factors behind this. Research showed that early diagnosis of cancer reduces the mortality rate and hence can improve the treatment outcome. As a result, scientists are trying to find out an easy, quick and reliable method of diagnosis of OSCC. Although scalpel (incisional) biopsy followed by histopathological examination is still the gold standard for the diagnosis of the oral lesion but in the case of behind the visible area and in restricted mouth opening it is very difficult to collect the representative specimen. Moreover, the procedure is invasive and needs special equipment and expertise. In this aspect, to avoid the risk of invasive procedures and pain, body fluid analysis is the area of interest of the researcher nowadays. Among the other body fluid, saliva is very easy to collect, non-invasive and might have the property to diagnose of OSCC because it remains with the contact with the lesion. It has plenty of flow and less costly than the others. LC-MS machine is now widely used for metabolomics analysis all over the world. It has the capacity to analyze a sample more effectively and within a very short time. Measuring the amino acid and other components from the saliva can easily be done by this method. Due to some diseases, amino acid concentration of body fluid differs according to several studies. The investigators believe that for the Bangladeshi population there are significant associations between several salivary amino acid levels and OSCC, which can be identified by LC-MS.
- General objective: To find out the association of salivary amino acid levels with oral squamous cell carcinoma (OSCC) identified by liquid chromatography-mass spectrometry.
- Place of study: Oral and Maxillofacial Surgery Department, Bangabandhu Sheikh Mujib Medical University (BSMMU)and Bangladesh Reference Institute for Chemical Measurements (BRICM), Science lab, Dhanmondi, Dhaka.
- Study Population: Patients and their attendants attending in outdoor and indoor clinic of Oral and Maxillofacial Surgery Department, BSMMU according to inclusion and exclusion criteria. Total sample size will be 110 and 55 in each group. Cases are the oral squamous cell carcinoma patients confirmed by incisional biopsy and controls are the relatively same age group and healthy individuals.
- Study sample: Patients attending to the Department of Oral \& Maxillofacial Surgery, histo-pathologically diagnosed as oral squamous cell carcinoma who will fulfill the selection criteria will be selected as cases. Control subjects will be taken from healthy individuals among the attendants of patients almost from the same age group of cases maintaining the inclusion criteria. The participants are classified into two goups Group A (Cases): Study group consists of 55 patients those having histopathologically confirmed Oral Squamous Cell Carcinoma (OSCC) Group B (Controls): This group consists of 55 healthy individuals with nothaving any history of cancer and without severe periodontal problems and dental caries.
- Study variables:
- Histopathology report
- Level of salivary Amino acids detected by Liquid chromatography-mass spectrometry (LC-MS)
- Ethical consideration: Ethical clearance for the study will be taken from the Institutional Review Board (IRB) of BSMMU prior to the commencement of this study. After the research protocol is approved by the committee, permission for the study will be taken from the Department of Oral and Maxillofacial Surgery, Bangabandhu Sheikh Mujib Medical University. The aims and objectives of the study along with its procedure, risks, stages and benefits of this study will be explained to the study subjects in an easily understandable local language. They will be assured that the risk of this research is minimum. But, this risk will be properly addressed by specialist doctor. If any problem arises related to the biopsy procedure or due to any step of this research activity, they will get the whole treatment in free of cost. During and after research program confidentiality would be maintained strictly. An ID number will be given to them and that will be helpful to the research program. All the papers belong to this ID number will be locked in office. Personal matter will not be used for analysis, producing article and release. Only the involved investigator will know all these and nobody will get their information. Their participation in this research program is absolutely voluntary. They can either deny participation or leave the research program at any time. That will not affect their treatment process. Their legal right will not be harmed by signing the consent form. A written informed consent will be taken from all the study subjects without exploiting any of their weakness. All the study subjects will be assured about their confidentiality and freedom to withdraw themselves from the study at any time.
- Implementation of results: The result might be helpful to find out the association betweensalivary amino acidlevelsand oral squamous cell carcinoma (OSCC) patients. Thus, might be helpful in early detection of OSCC. The data will be helpful for future research and that will be considered baseline information for public health department.
- Aim and Procedure:
The aim of the study is to find out the association of salivary amino acid levels with oral squamous cell carcinoma (OSCC).The study will be conducted at Oral and Maxillofacial Surgery Department of Bangabandhu Sheikh Mujib Medical University Patient with histologically confirmed OSCC will be enrolled as cases in the study by purposive convenient sampling technique to achieve the desired number. Approximately same number of the healthy individuals will be taken as control group for comparison. Then the saliva will be taken from the OSCC patient and from the control group. After taking in the sterile container and ensuring proper environment saliva sample will be carried to Designated Reference Institute for Chemical Measurements (DRICM), Science lab, Dhanmondi for analysis by liquid chromatography-mass spectrometry (LC-MS) machine. By this machine, the levels of 6 specific amino acids (Alanine, Valine, Glycine, Phenylalanine, Isoleucine, Lysine) will be measured. The data obtained from each individual will be recorded in predesigned data collection sheet separately. If participents are agreeing to participate in this research program, the responsible doctor will inform the participents in detail.
- Conditions
- Oral Squamous Cell Carcinoma
- Being tested
- Oral Squamous Cell Carcinoma
- Medical subject headings
- Squamous Cell Carcinoma of Head and Neck
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Oral Squamous Cell CarcinomaDiagnostic test
To identify the association of elevated level of specific amino acids in OSCC by Liquid Chromatography Mass Spectrometry
| Study group | Role | What they receive |
|---|---|---|
| Patients with Progressive Disease and without Progressive Disease | 1. Patients with Progressive Disease Patients with metastasis and/or recurrent OSCC were considered as a group of subjects with progressive disease.
2. Patients with without Progressive Disease Patients without metastasis and/or recurrent OSCC were considered as a group of subjects without progressive disease. Receives: Diagnostic Test: Oral Squamous Cell Carcinoma |
What is being measured
The primary outcome is the main question the study is designed to answer.
The primary outcome of the study to establish a diagnostic test in the early detection of OSCC.
- Total 110 samples, 55 in each group (case and control) will be included in the study and a questionnaire will be filled up by each participant based on their sociodemographic characteristics, personal habit and also the tumor staging of confirmed cancer cases.
Saliva metabolite profiling of six amino acids (Alanine, Valine, Glycine, Phenylalanine, Isoleucine, Lysine) will be performed using LCMS/MS system.
During metabolite profiling experiments, centroid data will be acquired for each sample from 50 to 1000 Da with a 0.10-sec scan time and a 0.01-sec interscan delay over an 18-min analysis time.
- The LCMS/MS data of OSCC and control saliva samples will be analyzed to identify potential discriminant variables. Selecting the method, investigator will create dataset, Researcher would like to (i) detect Peaks and (ii) collect markers. The investigators can create dataset display, and at this point, it is also possible to automatically print data into a text file.
Measured: From December,2020 to February, 2022
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Dec 2021
- Study start15 Dec 2020
- Primary completion20 Mar 2022 (estimated)
- Study completion30 Mar 2022 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Oral Squamous Cell CarcinomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Retrospective
- Enrolment
- 110 participants (estimated)
Sponsor and investigators
- Lead sponsor
- DR. MALA KHAN
- Sponsor type
- Other government
- Collaborators
- Bangladesh Reference Institute of Chemical Measurements (BRICM)
- Responsible party
- Sponsor-investigator, DR. MALA KHAN, Bangladesh Reference Institute of Chemical Measurements (BRICM)
- Investigators
- Dr. Dipayan Mojumder, BDS, Principal investigator, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05150509
- Sponsor's protocol ID
- ORAL SQUAMOUS CELL CARCINOMA
- Acronym
- OSCC
- Status last verified
- Feb 2022
- First submitted
- 25 Oct 2021
- Last updated
- 22 Feb 2022
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Feb 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Association of Salivary Amino Acid With Oral Squamous Cell Carcinoma Identified by Liquid Chromatography Mass Spectroscopy
- ClinicalTrials.gov ID
- NCT05150509
- Acronym / sponsor ID
- OSCC / ORAL SQUAMOUS CELL CARCINOMA
- Conditions
- Oral Squamous Cell Carcinoma
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 110 participants (estimated)
- Lead sponsor
- DR. MALA KHANOther government
- Collaborators
- Bangladesh Reference Institute of Chemical Measurements (BRICM)
- Study start
- 15 Dec 2020 (actual)
- Primary completion
- 20 Mar 2022 (estimated)
- Study completion
- 30 Mar 2022 (estimated)
- First posted
- 9 Dec 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Oral Squamous Cell Carcinoma (OSCC) is the most common oral malignancy worldwide. The prognosis of the OSCC patient is not significant despite the modern treatment facilities. Late presentation is one of the most crucial cause of this and for that reason, the importance of early diagnosis of OSCC should be the main concern. Till now, incisional biopsy followed by histopathological examination is the gold standard for diagnosis of oral cancer. The aim of the present study is to find out the association of salivary amino acid levels with oral squamous cell carcinoma, whether the levels are increased or decreased in the patient suffering from OSCC. This might be helpful for early diagnosis of oral cancer and better prognosis.
Detailed description
- Introduction: Oral cancer is an abnormal growth of tissue, originates from the tissue in and around the mouth which is uncoordinated with that of the surrounding normal tissue. Among all oral cancers, oral squamous cell carcinoma (OSCC) is the most common (90%) malignant epithelial neoplasm of the oral cavity. It is an alarming public health problem in the world due to its prevalence, high incidence rate and mortality. According to the recent data of GLOBOCAN 2020, 377713 newly diagnosed lip and oral cavity squamous cell carcinoma patients diagnosed worldwide which is about 2% of all cancer reported. Oral squamous cell carcinoma (OSCC) is the 6th most common cancer worldwide. Recent global reports suggest that the largest portion of the reported cases are from Asia (65.8%), but in the South Asia region, oral cancer is the 3rd most common cancer. One of the critical factor of the high mortality rate of OSCC is that initially many of the lesion is asymptomatic. As a result, they come at the late stage of the disease to the physician and ultimately have a poor prognosis. Research showed that, when an OSCC is in stage I, the 5-year survival rate is 80% but it drops to 20-40% when the disease is in stage IV. For the diagnosis of OSCC, after the initial clinical examination, incisional biopsy followed by histopathological examination is still considered as a gold standard, but the method has many limitations. Invasive procedure needs special expertise for taking biopsy sample from the representative areas and need expert histopathologist for confirmation. Moreover, taking a tissue sample from behind the visible area such as the base of the tongue, posterior pillar and incase of restricted jaw opening is very difficult or sometimes impossible. Human saliva is the secretion from three major salivary gland parotid, submandibular, sublingual and numerous minor glands lie just beneath the mucosa of the oral cavity. It consists of water (99.5%), inorganic salts and enzymes (0.2%) and proteins (0.3%). It is helpful for the diagnosis of periodontitis, diabetes mellitus, HIV, dengue, mumps even breast cancer, pancreatic cancer, gastric cancer, lung cancer and oral cancer. Additionally, taking saliva samples has many advantages. Taking saliva is easier, and needs no invasive procedure or expertise. Besides, it has a sufficient amount of production and can be taken by the patient himself making the sample taking procedure cheaper. Salivary amino acids are the important metabolites for the diagnosis of a cancer patient. Amino acid is the raw product of protein synthesis. For this, when a cancer patient passes through a hypermetabolic and hypercatabolic state, there is a chance of protein imbalance. As the investigators know that amino acids are the byproducts of protein, it can give us a hint for the state of imbalance due to any cancer including oral squamous cell carcinoma. In addition, changes in amino acid concentration in the body fluid of cancer patient is significant according to several studies Mass spectrometry is a currently used platform for proteomics or metabolomics in biomedical research. Like other spectrometry method such as gas chromatography-mass spectrometry (GC-MS), capillary electrophoresis-mass spectrometry(CE-MS), two-dimensional electrophoresis mass spectrometry (2DE-MS), matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF) and surface enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI-TOF), Liquid chromatography-mass spectrometry (LC-MS) is widely used nowadays. It allows a quick and efficient separation and characterization of analytes in a given sample. Thus, it can help in rapid diagnosis of any disease by automated analysis of amino acid profiles with minimum effort and expenses. Many studies were conducted using LC-MS machine for saliva analysis for the diagnosis of several diseases and found significant results. To the best of my knowledge, very few studies were done to find out the salivary amino acid level from the patient having suspected oral lesion by LC-MS. Moreover, no study was performed for oral lesion diagnosis by analysis of amino acid profile using LC-MS in Bangladesh. The aim of this study is to find out the association of specific salivary amino acid levels with the patient of OSCC by Liquid Chromatography-Mass Spectrometry (LC-MS).
- Rationale: OSCC is the 6th most common cancer worldwide, but in Asia the largest portion was reported recently and in South-east Asia, it is the 3rd most common cancer. Poor socio-economic condition, lack of consciousness and widely use of tobacco, betel quid chewing and alcohol intake are the main factors behind this. Research showed that early diagnosis of cancer reduces the mortality rate and hence can improve the treatment outcome. As a result, scientists are trying to find out an easy, quick and reliable method of diagnosis of OSCC. Although scalpel (incisional) biopsy followed by histopathological examination is still the gold standard for the diagnosis of the oral lesion but in the case of behind the visible area and in restricted mouth opening it is very difficult to collect the representative specimen. Moreover, the procedure is invasive and needs special equipment and expertise. In this aspect, to avoid the risk of invasive procedures and pain, body fluid analysis is the area of interest of the researcher nowadays. Among the other body fluid, saliva is very easy to collect, non-invasive and might have the property to diagnose of OSCC because it remains with the contact with the lesion. It has plenty of flow and less costly than the others. LC-MS machine is now widely used for metabolomics analysis all over the world. It has the capacity to analyze a sample more effectively and within a very short time. Measuring the amino acid and other components from the saliva can easily be done by this method. Due to some diseases, amino acid concentration of body fluid differs according to several studies. The investigators believe that for the Bangladeshi population there are significant associations between several salivary amino acid levels and OSCC, which can be identified by LC-MS.
- General objective: To find out the association of salivary amino acid levels with oral squamous cell carcinoma (OSCC) identified by liquid chromatography-mass spectrometry.
- Place of study: Oral and Maxillofacial Surgery Department, Bangabandhu Sheikh Mujib Medical University (BSMMU)and Bangladesh Reference Institute for Chemical Measurements (BRICM), Science lab, Dhanmondi, Dhaka.
- Study Population: Patients and their attendants attending in outdoor and indoor clinic of Oral and Maxillofacial Surgery Department, BSMMU according to inclusion and exclusion criteria. Total sample size will be 110 and 55 in each group. Cases are the oral squamous cell carcinoma patients confirmed by incisional biopsy and controls are the relatively same age group and healthy individuals.
- Study sample: Patients attending to the Department of Oral \& Maxillofacial Surgery, histo-pathologically diagnosed as oral squamous cell carcinoma who will fulfill the selection criteria will be selected as cases. Control subjects will be taken from healthy individuals among the attendants of patients almost from the same age group of cases maintaining the inclusion criteria. The participants are classified into two goups Group A (Cases): Study group consists of 55 patients those having histopathologically confirmed Oral Squamous Cell Carcinoma (OSCC) Group B (Controls): This group consists of 55 healthy individuals with nothaving any history of cancer and without severe periodontal problems and dental caries.
- Study variables:
- Histopathology report
- Level of salivary Amino acids detected by Liquid chromatography-mass spectrometry (LC-MS)
- Ethical consideration: Ethical clearance for the study will be taken from the Institutional Review Board (IRB) of BSMMU prior to the commencement of this study. After the research protocol is approved by the committee, permission for the study will be taken from the Department of Oral and Maxillofacial Surgery, Bangabandhu Sheikh Mujib Medical University. The aims and objectives of the study along with its procedure, risks, stages and benefits of this study will be explained to the study subjects in an easily understandable local language. They will be assured that the risk of this research is minimum. But, this risk will be properly addressed by specialist doctor. If any problem arises related to the biopsy procedure or due to any step of this research activity, they will get the whole treatment in free of cost. During and after research program confidentiality would be maintained strictly. An ID number will be given to them and that will be helpful to the research program. All the papers belong to this ID number will be locked in office. Personal matter will not be used for analysis, producing article and release. Only the involved investigator will know all these and nobody will get their information. Their participation in this research program is absolutely voluntary. They can either deny participation or leave the research program at any time. That will not affect their treatment process. Their legal right will not be harmed by signing the consent form. A written informed consent will be taken from all the study subjects without exploiting any of their weakness. All the study subjects will be assured about their confidentiality and freedom to withdraw themselves from the study at any time.
- Implementation of results: The result might be helpful to find out the association betweensalivary amino acidlevelsand oral squamous cell carcinoma (OSCC) patients. Thus, might be helpful in early detection of OSCC. The data will be helpful for future research and that will be considered baseline information for public health department.
- Aim and Procedure:
The aim of the study is to find out the association of salivary amino acid levels with oral squamous cell carcinoma (OSCC).The study will be conducted at Oral and Maxillofacial Surgery Department of Bangabandhu Sheikh Mujib Medical University Patient with histologically confirmed OSCC will be enrolled as cases in the study by purposive convenient sampling technique to achieve the desired number. Approximately same number of the healthy individuals will be taken as control group for comparison. Then the saliva will be taken from the OSCC patient and from the control group. After taking in the sterile container and ensuring proper environment saliva sample will be carried to Designated Reference Institute for Chemical Measurements (DRICM), Science lab, Dhanmondi for analysis by liquid chromatography-mass spectrometry (LC-MS) machine. By this machine, the levels of 6 specific amino acids (Alanine, Valine, Glycine, Phenylalanine, Isoleucine, Lysine) will be measured. The data obtained from each individual will be recorded in predesigned data collection sheet separately. If participents are agreeing to participate in this research program, the responsible doctor will inform the participents in detail.
Study design
- Observational model
- Case-control
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients with Progressive Disease and without Progressive Disease | – | Diagnostic Test: Oral Squamous Cell Carcinoma1. Patients with Progressive Disease Patients with metastasis and/or recurrent OSCC were considered as a group of subjects with progressive disease. 2. Patients with without Progressive Disease Patients without metastasis and/or recurrent OSCC were considered as a group of subjects without progressive disease. |
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Patients and their attendants attending in outdoor and indoor clinic of Oral and Maxillofacial Surgery Department, BSMMU according to inclusion and exclusion criteria. Total sample size will be 110 and 55 in each group. Cases are the oral squamous cell carcinoma patients confirmed by incisional biopsy and controls are the relatively same age group and healthy individuals.
Key inclusion criteria (6 listed)
- Age: 18-70 years.
- Both genders.
- Patient with histo-pathologically diagnosedoral squamous carcinoma
- Willing to participate in the study. Inclusion criteria for controls
- Healthy patients without any malignancy
Key exclusion criteria (5 listed)
- Patients with severe periodontitis and multiple carious teeth.
- Patients having other systemic diseases and cancer.
- Patients who cannot fulfill the inclusion criteria. Exclusion criteria for controls
- Having severe periodontal problemsor dental caries
- Suffering from any cancer
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Oral Squamous Cell CarcinomaTo identify the association of elevated level of specific amino acids in OSCC by Liquid Chromatography Mass Spectrometry | Diagnostic test | Patients with Progressive Disease and without Progressive Disease |
Primary outcome
The primary outcome of the study to establish a diagnostic test in the early detection of OSCC.
Time frame: From December,2020 to February, 2022
1. Total 110 samples, 55 in each group (case and control) will be included in the study and a questionnaire will be filled up by each participant based on their sociodemographic characteristics, personal habit and also the tumor staging of confirmed cancer cases. Saliva metabolite profiling of six amino acids (Alanine, Valine, Glycine, Phenylalanine, Isoleucine, Lysine) will be performed using LCMS/MS system. During metabolite profiling experiments, centroid data will be acquired for each sample from 50 to 1000 Da with a 0.10-sec scan time and a 0.01-sec interscan delay over an 18-min analysis time. 3. The LCMS/MS data of OSCC and control saliva samples will be analyzed to identify potential discriminant variables. Selecting the method, investigator will create dataset, Researcher would like to (i) detect Peaks and (ii) collect markers. The investigators can create dataset display, and at this point, it is also possible to automatically print data into a text file.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Feb 2022.
- Individual participant dataSharing planned: No
Related trials for Oral Squamous Cell Carcinoma
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingPhase 2
Proton Spatially Fractionated Radiotherapy or Photon Stereotactic Body Radiotherapy in Combination With Pembrolizumab Before Surgery for the Treatment of Locally Advanced and Radiation-Naive Locoregionally Recurrent Oral Cavity Cancer, OSPRI Trial
Locally Advanced Oral Cavity Squamous Cell Carcinoma, Locally Recurrent Oral Cavity Squamous Cell Carcinoma
RecruitingObservational study
Defining the Natural History of Squamous Cell Carcinoma in Fanconi Anemia
Fanconi Anemia, Inherited Bone Marrow Failure Syndrome
RecruitingPhase 1/2
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
RecruitingPhase 3
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Dr. Dipayan Mojumder, BDS principal investigator
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Oral Squamous Cell Carcinoma, run by DR. MALA KHAN at 2 sites in Bangladesh.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 22 Feb 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Bangladesh. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Mala Khan, Dr. (+8801715032057, malakhan_07@yahoo.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The primary outcome of the study to establish a diagnostic test in the early detection of OSCC. (time frame: From December,2020 to February, 2022). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Feb 2022.